Search Results for "R"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for R. Results 521 to 530 of 1003 total matches.

Raloxifene (Evista) for Breast Cancer Prevention in Postmenopausal Women

   
The Medical Letter on Drugs and Therapeutics • May 08, 2006  (Issue 1234)
R. Simons, M.D., University of Manitoba Neal H. Steigbigel, M.D., New York University School ...
Preliminary results from a new study, unpublished but reported in a press release from the National Cancer Institute and widely disseminated in the public press, suggest that raloxifene (Evista) might be a better choice than tamoxifen (Nolvadex, and others) for prevention of breast cancer in high-risk postmenopausal women.
Med Lett Drugs Ther. 2006 May 8;48(1234):37 |  Show IntroductionHide Introduction

Mumps Outbreak Recommendations

   
The Medical Letter on Drugs and Therapeutics • Jun 05, 2006  (Issue 1236)
R. Simons, M.D., University of Manitoba Neal H. Steigbigel, M.D., New York University School ...
A large mumps outbreak that began in Iowa in December 2005 has spread. About 40% of the cases have been in people 18-25 years old, many of whom are college students and had been vaccinated against the disease.
Med Lett Drugs Ther. 2006 Jun 5;48(1236):45 |  Show IntroductionHide Introduction

Finasteride for Prevention of Prostate Cancer

   
The Medical Letter on Drugs and Therapeutics • Jun 30, 2008  (Issue 1289)
. Roden, M.D., Vanderbilt University School of Medicine F. Estelle R. Simons, M.D., University ...
Patients are asking physicians about an article on the front page of the June 15th New York Times, in which some prostate cancer experts were quoted as suggesting that men 55 and older might be well advised to take finasteride (Proscar, and others) to prevent prostate cancer.
Med Lett Drugs Ther. 2008 Jun 30;50(1289):49-50 |  Show IntroductionHide Introduction

Advertisements for TNF Inhibitors

   
The Medical Letter on Drugs and Therapeutics • Nov 17, 2008  (Issue 1299)
. Roden, M.D., Vanderbilt University School of Medicine F. Estelle R. Simons, M.D., University ...
Some tumor necrosis factor (TNF) inhibitors are being promoted on the internet directly to the public for use in psoriasis (www.yahoo.com).
Med Lett Drugs Ther. 2008 Nov 17;50(1299):89 |  Show IntroductionHide Introduction

Low-Voltage Electronic Diagnostic Devices

   
The Medical Letter on Drugs and Therapeutics • Dec 01, 2008  (Issue 1300)
., University Hospital, Copenhagen Dan M. Roden, M.D., Vanderbilt University School of Medicine F. Estelle R ...
Health care professionals may be asked about lowvoltage electronic devices now being used to diagnose and/or treat a number of health problems. Most are galvanometers that measure skin resistance to an electric current. The FDA classifies "devices that use resistance measurements to diagnose and treat various diseases" as Class III devices that require FDA approval prior to marketing. None of the devices reviewed here has such approval.
Med Lett Drugs Ther. 2008 Dec 1;50(1300):95-6 |  Show IntroductionHide Introduction

In Brief: Extended-Release Amoxicillin for Strep Throat

   
The Medical Letter on Drugs and Therapeutics • Mar 09, 2009  (Issue 1307)
Hospital, Copenhagen Dan M. Roden, M.D., Vanderbilt University School of Medicine F. Estelle R. Simons ...
The FDA has approved an extended-release formulation of amoxicillin (Moxatag – MiddleBrook) for once-daily treatment of pharyngitis or tonsillitis caused by Streptococcus pyogenes in adults and children ≥12 years old. Approval was based on an unpublished study that found once-daily treatment with Moxatag 775 mg for 10 days non-inferior to penicillin V 250 mg four times a day for 10 days in eradication of S. pyogenes.For decades, the drug of choice for oral treatment of streptococcal pharyngitis in adolescents and adults has been penicillin V 250 mg taken three or four times a day.1...
Med Lett Drugs Ther. 2009 Mar 9;51(1307):17 |  Show IntroductionHide Introduction

Drugs for MRSA with Reduced Susceptibility to Vancomycin

   
The Medical Letter on Drugs and Therapeutics • May 04, 2009  (Issue 1311)
., University Hospital, Copenhagen Dan M. Roden, M.D., Vanderbilt University School of Medicine F. Estelle R ...
The recent Medical Letter article on vancomycin dosing and monitoring briefly mentioned use of an alternative antibiotic for treatment of methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to vancomycin. Some readers have asked for more information on this subject.

Click here to view the free full article.
Med Lett Drugs Ther. 2009 May 4;51(1311):36 |  Show IntroductionHide Introduction

Colon Cleansing

   
The Medical Letter on Drugs and Therapeutics • May 18, 2009  (Issue 1312)
Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine F. Estelle R. Simons, M.D., University ...
Web sites and blogs are advising patients that periodic "cleansing" of the colon is necessary to rid the body of toxins.
Med Lett Drugs Ther. 2009 May 18;51(1312):39-40 |  Show IntroductionHide Introduction

In Brief: Prevention of Stroke in Patients with Atrial Fibrillation

   
The Medical Letter on Drugs and Therapeutics • Jun 01, 2009  (Issue 1313)
. Mukherjee, M.D., F.A.C.C., Yale School of Medicine F. Estelle R. Simons, M.D., University of Manitoba ...
Atrial fibrillation increases the risk of stroke by a factor of 5. A randomized controlled trial (ACTIVE W) in 6706 patients with atrial fibrillation and one or more additional risk factors (≥75 years old; hypertension; previous stroke, transient ischemic attack or non- CNS embolus; left ventricular ejection fraction <45%; peripheral vascular disease; or 55-74 years old plus diabetes or coronary artery disease) found that a vitamin K antagonist such as warfarin (Coumadin, and others) was superior to clopidogrel (Plavix) plus aspirin in preventing vascular events, especially ischemic...
Med Lett Drugs Ther. 2009 Jun 1;51(1313):41 |  Show IntroductionHide Introduction

In Brief: Biennial IV Zoledronic Acid (Reclast) for Prevention of Osteoporosis

   
The Medical Letter on Drugs and Therapeutics • Jun 29, 2009  (Issue 1315)
., University Hospital, Copenhagen Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine F. Estelle R ...
The FDA, which had previously approved intravenous (IV) administration of 5 mg of zoledronic acid (Reclast – Novartis) once a year for treatment of postmenopausal osteoporosis (Med Lett Drugs Ther 2007; 49:89), has now approved the same dose for use once every 2 years to prevent osteoporosis in postmenopausal women with osteopenia.Clinical Studies – In an unpublished study summarized in the package insert, 224 women with osteopenia ≤5 years after menopause were given an IV infusion of zoledronic acid 5 mg or placebo; 2 years later, total hip bone mineral density (BMD) had increased by...
Med Lett Drugs Ther. 2009 Jun 29;51(1315):49 |  Show IntroductionHide Introduction